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Abstract
Background: The Angioedema Quality of Life (AE-QoL) is the first patient reported outcome measure developed
for the assessment of quality of life (QoL) impairment in patients with recurrent angioedema (RAE). This study aimed to
evaluate the clinimetric properties of the AE-QoL in Thai patients and to establish categories of QoL impairment
assessed by the AE-QoL.
Methods: The validated Thai version of the Dermatology Life Quality Index (DLQI) and Patient Global Assessment
of Quality of Life (PGA-QoL) were used to comparatively evaluate the Thai version of AE-QoL. Spearman correlations
between the Thai AE-QoL and two other standard measurements (DLQI and PGA-QoL) were investigated to determine
convergent validity. The Thai DLQI and PGA-QoL were used to categorize patients according to their QoL. Known-
group validity of the Thai AE-QoL was later analyzed. The reliability of the Thai AE-QoL was investigated using Cronbach’s
alpha and intraclass correlation. Three different approaches including the distribution method, receiver operating
characteristic curve analysis, and the anchor based-method were used for the interpretability.
Results: A total of 86 patients with RAE with a median age of 38.0 ± 15.1 years (range 18–76) were enrolled. Of
those, 76 patients (88%) had RAE with concomitant wheals, and 10 patients (11.6%) had RAE only. The AE-QoL
assessed RAE-mediated QoL impairment with high convergent validity and known-groups validity, high internal
consistency and test-retest reliability, and good sensitivity to change. Although the AE-QoL did not differentiate
between patients with moderate and large effect as measured by PGA-QoL or DLQI in this study, AE-QoL total
values of 0–23, 24 to 38, and ≥ 39 could define patients with “no effect”, “small effect”, and “moderate to large
effect” of RAE on their QoL, respectively.
Conclusions: This study supports the validity and reliability of the Thai version of the AE-QoL, which is a very
different language from the original version. Categories allow to classify the effect of RAE on patients’ QoL as
“none”, “small”, and “moderate to large”. Further studies are needed to confirm the applicability of AE-QoL in
other Asian populations”.
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Background
Recurrent angioedema (RAE) is characterized by the
unpredictable, sudden and recurrent onset of nonpitting
swelling of the skin, subcutaneous tissues, and/or
mucous membranes [1]. Angioedema attacks may be
painful, disabling, and disfiguring depending on their
duration, location and the extent of swelling. Swellings
in RAE patients can cause itch or a burning sensation,
often they do not. Cases of RAE with upper airway
involvement can be an emergency and life-threatening
condition.
RAE is classified into mast cell mediator-mediated and
bradykinin-mediated, based on the underlying patho-
genic mechanisms [2]. In clinical practice, RAE most
commonly occurs in chronic spontaneous urticaria
(CSU) patients, with or without wheals [3]. RAE is
associated with markedly impaired health-related quality
of life (HRQoL) [4, 5]. Effective management of RAE
requires the use of angioedema specific instruments
designed to evaluate patients’ impairment in HRQoL.
For assessing HRQoL of angioedema patients, the
Angioedema Quality of Life Questionnaire (AE-QoL) [6]
and the Hereditary Angioedema Quality of Life Ques-
tionnaire (HAE- QoL) have been developed [7–9]. The
HAE-QoL assesses HAE-specific effects on QoL,
whereas the AE-QoL was developed for the use in pa-
tients with all forms of RAE including HAE. The original
German version of the AE-QoL consists of 17 questions
in 4 domains (functioning, fatigue/mood, fear/shame,
and food) that collectively evaluate the extent of RAE-
dependent QoL impairment during the previous 4 weeks.
Each AE-QoL question has 5 answer options (scored 1–
5), with lower and higher scores indicting less and more
adverse impact, respectively. The total score is calcu-
lated, which is then transformed into a linear scale that
ranges from 0 to 100, with a score of 100 indicating the
worst possible impairment of HRQoL [6]. The AE-
QoL was shown to be valid and reliable for use in
clinical practice and has been used in multiple ran-
domized controlled trials [10–15]. The minimal clinic-
ally important difference (MCID), which is defined as
the least difference in a score that patients can notice
the improvement in their HRQoL, was proposed to
be > 6 points [6]. The AE-QoL has been translated
and culturally adapted for the use in 25 countries in
29 languages [16].
As of now, there is the lack of and need for
categorization/banding of HRQoL impairment in RAE
patients. Also, we are lacking validated version of
patient-reported outcome (PRO) outcome measures for
assessing QoL impairment in Asian patients with RAE.
Accordingly, this study generated the Thai version of the
AE-QoL, evaluated its clinimetric properties in an Asian
population of RAE patients, specifically in Thailand, and
established categories of AE-QoL-assessed QoL impair-
ment in this RAE population.
Methods
Generation of the Thai AE-QoL
Formal permission was given by MOXIE GmbH (moxie-
gmbh.de/, Berlin, Germany) to translate the original
German version of the AE-QoL into Thai, and to valid-
ate the translated instrument [16]. The AE-QoL were
independently translated into Thai by two native Thai
speakers with command of the German language. Both
Thai versions were then reviewed and revised by derma-
tologists with subspecialty expertise in allergy with the
objective of achieving unanimous agreement for each
item. The final Thai version of each instrument was then
independently back-translated into German by two bilin-
gual translators. The two back-translated German
versions were then reviewed by the German developers
of the original instrument.
Misconceptions or misinterpretations during the
translation process were resolved via a cooperative
review and editing process that included the Thai
research team and the instrument developers. After
consensus was reached among all assessors, cognitive
debriefing was performed with representatives of the tar-
get population and target language group to evaluate if
the responders understand the questionnaire as intended
[17, 18]. The final Thai version of the AE- QoL was
tested in 10 Thai RAE patients. This test revealed no
points of contention or misinterpretation. The final Thai
versions of the AE-QoL was then approved and used in
this study.
Patients and conduct of study
This study was approved by the Siriraj Institutional Re-
view Board (SIRB), Faculty of Medicine Siriraj Hospital,
Mahidol University, Bangkok, Thailand (COA no. Si271/
2017). Adult Thai RAE patients aged 18 years or older
attending the Urticaria Center of Reference and Excel-
lence [19] of the Department of Dermatology, Siriraj
Hospital during May 2017 to May 2018 were invited to
voluntarily participate. Siriraj Hospital is Thailand’s lar-
gest national tertiary referral center. Patients with RAE
were defined as patients with the unpredictable, sudden
and recurrent onset of nonpitting swellings of the skin,
subcutaneous tissues, and/or mucous membranes for
longer than 6 weeks [1]. Patients who had literacy diffi-
culties, dermatologic diseases other than RAE, and/or
mental diseases were excluded. Standard treatment for
RAE was given to all patients regardless of their partici-
patory status in this study. This study complied with the
principles set forth in the Declaration of Helsinki (1964)
and all of it subsequent amendments, and written
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informed consent was obtained from all participating
patients.
Patient HRQoL questionnaires used to compare with the
Thai version of the AE-QoL
The validated Thai version of the dermatology life quality
index (DLQI)
The DLQI is a general dermatologic HRQoL question-
naire that was established by Finlay et al. in 1994 [20].
The DLQI consists of 10 items, with a minimum and
maximum score of 0 and 30, respectively. Total DLQI
scores are categorized into one of the following five
groups: 0–1 = no effect, 2–5 = small effect, 6–10 =
moderate effect, 11–20 = very large effect, and 21–30 =
extremely large effect. The Thai version of the DLQI
was used [21].
Patient global assessment of quality of life (PGA-QoL)
The PGA-QoL is a patient evaluation instrument for
assessing HRQoL during the preceding four-week period.
A 5-point Likert-scale is used to rate level of effect, as fol-
lows: 0 = no effect, 1 =mild effect, 2 =moderate effect, 3 =
severe effect, and 4 = very severe effect [22, 23].
At baseline, patients were informed how to complete
the following questionnaires: Thai AE-QoL, Thai DLQI,
and PGA-QoL. After patients acknowledged understand-
ing of how to complete all three questionnaires, they
were asked to complete the Thai AE-QoL, Thai DLQI,
and PGA-QoL by themselves at the clinic. After 4 weeks
of treatment (2nd visit), all of the questionnaires were
once again completed by the patients in the clinic.
Statistical analysis
Consensus-based Standards for the Selection of Health
Measurement Instruments (COSMIN), a standard proto-
col for evaluating the methodologic quality of studies in
health measurement instruments, was applied in this
study [24]. The Statistical Package for the Social Sci-
ences for Windows, Version 18.0 (SPSS Inc., Chicago,
IL, USA) was used to analyze data. P- values of less than
or equal to 0.05 were considered to be statistically
significant.
Assessment of AE-QoL validity
Convergent validity indicates the correlation between the
Thai AE-QoL and other standard measurements for
HRQoL (DLQI and PGA-QoL). Spearman correlation co-
efficients of < 0.3, 0.3–0.6, and > 0.6 were considered weak,
moderate, and strong correlations, respectively [25].
Known-group validity demonstrates the ability of the
AE-QoL to discriminate groups that are assumed to be
different. For HRQoL, patients were classified into three
groups using the DLQI and PGA-QoL scores in this
study, as follows: (i) ‘no effect’ (DLQI scores of 0–1,
PGA- QoL score of 0); (ii) ‘small effect’ (DLQI scores of
2–5, PGA-QoL score of 1); and, (iii) ‘moderate to large
effect’ (DLQI scores of 6–30, PGA-QoL scores of 2–4).
Assessment of AE-QoL reliability
Cronbach’s α reliability coefficient was used to analyze
internal consistency. Excellent, good, and acceptable reli-
ability were defined as α values of ≥0.9, 0.7 ≤ α < 0.9,
0.6 ≤ α < 0.7, respectively [26]. Internal consistency deter-
mines the homogeneity of AE-QoL domains, which can
indicate whether it is appropriate to calculate a total
score. The four domain scores of the AE-QoL were in-
vestigated for internal consistency in each domain.
Test-retest reliability assesses the consistency of scores
across multiple administrations. Stable patients should
have comparable scores at two different administrations.
Data from patients with no change in PGA-QoL score
(stable in HRQoL) during 4 weeks of treatment was used
to determine test-retest reliability. Intraclass correlation co-
efficient (ICC) values of < 0.40, 0.4–0.75, and > 0.75 indi-
cate poor, average, and strong reliability, respectively [27].
Assessment of AE-QoL sensitivity to change
Sensitivity to change is defined as the ability of an
instrument to detect change over time, regardless of
whether the change is meaningful [28]. Correlation coef-
ficients of 0.1–0.3, 0.3–0.5, and > 0.5 were considered
weak, moderate, and large correlations, respectively [29].
At least moderate correlation between an instrument
and a standard comparative measure was required to
further analyze AE-QoL interpretability in this study.
Assessment of AE-QoL interpretability
Interpretability is the ability of an instrument to trans-
form qualitative meaning to quantitative scores, i.e. the
degree to which the values obtained by the use of the in-
strument produce information relevant to the patient
and the physician in relation to the measured construct.
Interpretability is composed of the minimal clinically
important difference (MCID) and categorization. The
MCID is defined as the smallest difference in a score
that a patient can recognize as meaningful improvement
[30, 31]. Different approaches were used to define the
MCID are described, as follows:
i. Distribution method (MCID-1) indicates the
numerical distribution of values. The standard error
of measurement (SEM) is widely accepted to
represent the MCID of an instrument [32–34]. The
calculation of SEM was (1-reliability of the Thai
AE-QoL)1/2 × the SD of the Thai AE-QoL at
baseline.
ii. Receiver operating characteristic (ROC) curve
analysis (MCID-2) shows the sensitivity and
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specificity over the range of absolute reductions in
scores that can be used to identify “improvement”
[34, 35]. Area under the curve (AUC) values of 1,
0.9, 0.8, 0.7, and 0.5 were interpreted as perfect,
excellent, good, fair, and no better than chance,
respectively [36].
iii. Anchor-based approach (MCID-3) compares
changes in scores to an anchor value. MCID-3 is
the difference between the mean “improvement”
score and the mean “worsening/stable” score. Pa-
tients with a decrease in PGA-QoL score of ≥1 and
patients with an increased or unchanged PGA-QoL
score were defined as ‘improvement’ and ‘worsening
or stable’ HRQoL, respectively.
Categorization of effects of RAE on quality of life
Categorization is the process of determining cutoff
scores for a measurement instrument that are then used
to categorize patients into different groups. The DLQI
and PGA-QoL were used to categorize patients into “no
effect” (DLQI = 0–1, PGA-QoL = 0), “small effect”
(DLQI = 2–5, PGA-QoL = 1), “moderate effect” (DLQI =
6–10, PGA-QoL = 2), and “large and very large effect”
(DLQI = 11–30, PGA-QoL = 3–4).
Results
A total of 86 patients with RAE with a median age of
38.0 ± 15.1 years (range 18–76) were enrolled in this
study. Of those, 76 patients (88%) had RAE with con-
comitant wheals, and 10 patients (11.6%) had RAE only.
Of 10 patients who had RAE without wheals, 9 and 1
patients had idiopathic angioedema, and angiotensin-
converting enzyme inhibitor-induced angioedema, re-
spectively. Demographic data, scores at baseline, and
treatments are shown in Table 1. AE- QoL scores were
observed to be normally distributed. The mean AE-QoL
scores at baseline was 26.6 ± 20.7.
The AE-QoL is a valid tool for assessing RAE-mediated
QoL impairment
The AE-QoL showed high convergent validity, with
strong positive correlations between AE-QoL and DLQI
total score values (r = 0.72, p < 0.0001) and between AE-
QoL total score values and PGA-QoL values (r = 0.70,
p < 0.0001).
The AE-QoL also showed high known-groups validity
as it was able to discriminate among patients who
showed differences in HRQoL impairment as assessed
by the use of the PGA-QoL and the DLQI. Figure 1
demonstrates that the differences between the mean AE-
QoL scores of patients with no effect and a small effect
(p < 0.0001, p = 0.019) and with a small effect and a
moderate to large effect (p = 0.03, p = 0.014) were signifi-
cant. Overall, there were also significant differences in
the mean AE-QoL score among patients with no effect,
small effect, and moderate to large effect on HRQoL
(p < 0.0001). However, the AE-QoL did not differentiate
between patients with moderate and large effect as mea-
sured by PGA-QoL or DLQI. A statistical significance
was not achieved when using the DLQI or the PGA-
QoL to classify patients as those with “no effect”, a
“small effect”, a “moderate effect”, and a “large effect”.
The AE-QoL shows high internal consistency and test-
retest reliability
All Cronbach’s α values were higher than 0.72, which
indicates good to excellent internal consistency of the
Thai AE-QoL. Forty-four patients who had no change in
HRQoL (no change in PGA-QoL score) during 4 weeks
were analyzed for intraclass correlation coefficients
(ICCs). The ICC was 0.76 for the AE-QoL total score,
which indicates strong intra-rater reliability. The ICCs
(range: 0.64–0.75) for the AE-QoL domains were aver-
age (Table 2).
The AE-QoL shows good sensitivity to change
The correlation between AE-QoL score changes and
changes in PGA-QoL and DLQI were 0.39 and 0.42, re-
spectively (p < 0.0001). This allowed us to further analyze
MCID.
The MCID-1 indicates the numerical distribution of
values, The MCID-1 values using Cronbach’s α value,
and ICC value were 5.07, and 10.14, respectively. For
MCID-2, the sensitivity and specificity over the range of
absolute reductions in scores that can be used to identify
“improvement”, 30 and 56 patients were defined as ‘im-
provement’ and ‘worsening/stable’, respectively. An AUC
of 0.81 indicated that AE-QoL is a good tool for detect-
ing clinically meaningful improvement. Changes in AE-
QoL total score of 6 and 7 had good sensitivity (73.2%)
and specificity (76.7%) for defining patients with mean-
ingful improvement in HRQoL (Table 3). For MCID-3,
the difference in the mean total AE-QoL score between
‘improvement’ patients and ‘worsening/stable’ patients
was 11.83.
Categorization of AE-QoL-assessed effects of RAE on QoL
The AUCs for classifying patients into the “no effect”
group using PGA-QoL and DLQI were 0.88 and 0.85,
respectively (Table 4). AE-QoL total scores of 23 and 25
should be used to differentiate patients between “no
effect” and “small to large effect” using PGA-QoL and
DLQI, respectively. To classify patients into the ‘moder-
ate to large effect’ group, the AUC values using PGA-
QoL and DLQI were 0.87, and 0.86, respectively. Using
PGA-QoL and DLQI, patients with AE-QoL total scores
higher than 38 and 36 would be those with ‘moderate to
large effect’ on HRQoL.
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Discussion
This study is the first to validate the AE-QoL in Asia.
More importantly, it provides, for the first time, AE-QoL
categories that define patients with “no effect”, a “small
effect”, and a “moderate to large effect” of RAE on
HRQoL.
We found the AE-QoL to be a valid tool for assessing
and differentiating levels of HRQoL impairment in Asian
patients with angioedema, as shown by the strong
correlations between AE-QoL and DLQI, and between
AE-QoL and PGA-QoL. It is very important for an in-
strument to be able to detect meaningful improvement
or patient responsiveness to change. In the original ver-
sion (German version) of the AE-QoL, a change in the
total score of > 6 was identified as the MCID [37]. It is
generally accepted that MCID values depend on the
study population and the clinical context. The determin-
ation of the MCID should be based on the anchor-based
Table 1 Demographic and clinical characteristics of patients with recurrent angioedema (RAE) (n = 86) as well as their response to
treatment and quality of life impairment as assessed by use of the Thai Angioedema Quality of Life questionnaire (AE-QoL), the Thai






RAE without wheals 10 (11.6%)
RAE with wheals 76 (88.0%)
Range of scores (total score)
Thai AE-QoL 0–79.4 (100)
Thai DLQI 0–23 (30)
PGA-QoL 0–3 (4)
Disease severity of urticaria of 76 RAE patients with wheals
Urticaria activity score over 7 days (UAS7), n (%)
Urticaria-free (UAS7 = 0) 18 (23.7%)
Well-controlled CSU (UAS7 = 1–6) 13 (17.1%)
Mild activity CSU (UAS7 = 7–15) 26 (34.2%)
Moderate activity CSU (UAS7 16–27) 14 (18.4%)
Severe activity CSU (UAS7 = 28–42) 5 (6.6%)
Treatment, n (%)
H1-antihistamines 74 (86.0%)
H1-antihistamines + prednisolone 8 (9.3%)
H1-antihistamines + omalizumab 4 (4.7%)
Impairment of health-related quality of life using:
- PGA-QoL questionnaire, n (%) AE-QoL total value mean ± SD (median) 1st quartile 3rd quartile
None 11.2 ± 14.2 (5.9) 0 19.1 35 (40.7%)
Mild 29.9 ± 13.2 (32.4) 20.6 38.2 31 (36.0%)
Moderate 49.3 ± 17.6 (52.2) 34.9 67.3 12 (14.0%)
Severe 46.9 ± 20.4 (42.6) 34.6 61.8 8 (9.3%)
Very severe 0 0 0 0 (0.0%)
- DLQI questionnaire, n (%)
No effect 11.6 ± 13.6 (5.9) 0 19.9 33 (38.4%)
Small effect 26.0 ± 15.3 (24.3) 16.9 34.6 22 (25.6%)
Moderate effect 39.7 ± 17.3 (38.2) 33.1 49.3 13 (15.1%)
Very large effect 42.2 ± 19 (42.6) 35.7 61.8 18 (20.9%)
Extremely large effect 0 0 0 0 (0.0%)
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Fig. 1 The Thai version of the Angioedema Quality of Life (AE-QoL) questionnaire can differentiate patients with recurrent angioedema (RAE)
who differ in their quality of life (QoL) impairment as assessed by the use of the Patient Global Assessment of Quality of Life, PGA- QoL, (a) and
the Dermatology Life Quality Index, DLQI (b)
Table 2 Internal consistency of the Thai version of the Angioedema Quality of Life (AE-QoL) questionnaire
Domain Items Mean score (0–100) SD Cronbach’s α* (n = 86) ICC**
(n = 44)
Total score 26.55 20.70 0.94 0.76
Domain 1 (functioning) 1,2,3,4 20.49 23.83 0.94 0.75
Domain 2 (fatigue/mood) 6,7,8,9,10 23.66 22.33 0.86 0.64
Domain 3 (fear/shame) 12,13,14,15,16,17 35.17 28.34 0.92 0.64
Domain 4 (nutrition/food) 5,11 25.87 27.77 0.72 0.66
Abbreviation: SD, standard deviation; ICC, intraclass correlation coefficient
*Cronbach’s alpha values reflect analysis of data from 86 patients that completed the Thai AE-QoL questionnaire for the first time
**ICC values reflect the analysis of data from 44 patients who had stable disease (no change in Patient Global Assessment of Quality of Life questionnaire) after 4
weeks of treatment
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method or a ROC approach rather than the distribution
method as the latter relies on statistical properties and
its usefulness in clinical practice is questionable. Thus,
three different methods of calculating MCID have been
used in this study and yielded MCIDs that ranged from
5.07 to 11.83. However, ROC curve analysis revealed
that changes in AE-QoL scores of 6 or 7 had both good
sensitivity (73.2%) and good specificity (76.7%) for defin-
ing meaningful change according to the judgment of the
patient. We, therefore, adopted an MCID of > 6 points,
which is the same as the original version, to facilitate
consistency between versions in both clinical research
and routine clinical practice settings.
According to the results of previous study, the linear
correlation between AE-QoL total score and self-rated
HRQoL impairments was well-demonstrated [6]. How-
ever, the categorization of the AE-QoL score was not
established. This study provides additional information
on the interpretation of the AE-QoL with regard to
categorization, which is essential for the interpretation
of qualitative meaning to quantitative scores [38]. In our
study, only three groups of patients can be categorized;
those with no effect, a small effect, and a moderate to
large effect of their RAE on their QoL as a statistical sig-
nificance was not achieved when using the DLQI or the
PGA-QoL to classify patients as those with “no effect”, a
Table 3 Changes in AE-QoL total score to identify “improvement” (decrease in PGA-QoL score of ≥1) and “worsening/stable”
(increased or unchanged PGA-QoL score)
Changes in AE-QoL
total score
Sensitivity (%) (patients correctly classified
as worsening/stable)
Specificity (%) (patients correctly classified
as improvement)
Accuracy (%) (proportion of correctly
classified patients)
5 64.3% 76.7% 68.6%
6 73.2% 76.7% 74.4%
7 73.2% 76.7% 74.4%
8 75.0% 70.0% 73.3%
9 78.6% 70.0% 75.6%
10 78.6% 70.0% 75.6%
AUC 0.81 (0.72–0.91)
Abbreviations: AE-QoL, Angioedema quality of life; PGA-QoL, Patient global assessment quality of life; AUC, Area under the curve
Table 4 Cutoff values of the Angioedema Quality of Life (AE-QoL) questionnaire that differentiate patients with “no effect” from
patients with “moderate to large effect” on health-related quality of life (HRQoL) using the Patient Global Assessment Quality of Life
(PGA-QoL) and the Dermatology Life Quality Index (DLQI)
Patients with no effect on HRQoL using:
PGA-QoL score of 0 DLQI score of 0–1
AE-QoL score Sensitivity (%) Specificity (%) Accuracy (%) Sensitivity (%) Specificity (%) Accuracy (%)
22 85.7% 80.4% 82.6% 78.8% 73.6% 75.6%
23 88.6% 80.4% 83.7% 81.8% 73.6% 76.7%
24 88.6% 78.4% 82.6% 84.8% 73.6% 77.9%
25 88.6% 78.4% 82.6% 84.8% 73.6% 77.9%
26 88.6% 74.5% 80.2% 87.9% 71.7% 77.9%
AUC 0.88 (0.80–0.96) 0.85 (0.77–0.94)
Patients with moderate to large effect on HRQoL using:
PGA-QoL score of 2–4 DLQI score of 6–30
AE-QoL score Sensitivity (%) Specificity (%) Accuracy (%) Sensitivity (%) Specificity (%) Accuracy (%)
35 78.8 75.0% 77.9% 89.1% 74.2% 83.7%
36 78.8 75.0% 77.9% 89.1% 74.2% 83.7%
37 81.8 75.0% 80.2% 90.9% 71.0% 83.7%
38 81.8 75.0% 80.2% 90.9% 71.0% 83.7%
39 87.9 65.0% 82.6% 92.7% 54.8% 79.1%
AUC 0.87 (0.78–0.95) 0.86 (0.77–0.95)
Abbreviation: AUC, Area under the curve Bold entries indicate the most important results as discussed in the text
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“small effect”, a “moderate effect”, and a “large effect”.
The reason is that we had a limited number of patients
with severe or large effects on QoL. The prevalence of
RAE varies depending on geographic regions, the preva-
lence of RAE was found to be low in Thailand [1]. The
previous study and this study showed that HAE is
uncommon in the Thai population [1]. Generally, the
disease activity of HAE is more severe than that of other
forms of angioedema [39]. Accordingly, our patients, on
average, had less severe RAE as compared to other pop-
ulations in Western countries [1, 40–44].
The maximum values to classify patients into “no ef-
fect” group were 23 and 25 using PGA-QoL and DLQI,
respectively. The maximum value of 23 should be used
as the cutoff score for the “no effect” category, as it had
a higher AUC value than that of 25. Similarly, the mini-
mum values to classify patients as those with a moderate
to large effect were 38 and 36 using PGA-QoL and
DLQI, respectively. The value of 38 should be chosen
the cutoff value, as it had a higher AUC than that of 36.
Thus, we propose that AE-QoL total score values from 0
to 23, from 24 to 38, and ≥ 39 define patients with “no
effect”, a “small effect”, and a “moderate to large effect”
of their RAE on their HRQoL, respectively. To provide
a clinical perspective on this AE-QoL categorization: In
the recent X-ACT study, in CSU patients with angio-
edema refractory to H1-antihistamine, patients had a
“very large” negative impact on their HRQoL as
reflected by the mean DLQI total score of 14.6 at base-
line. The mean AE-QoL total score at baseline of these
patients was 56.2. Using our AE-QoL categorization,
the patients in this study fall into the category “moder-
ate to large effect” of RAE on HRQoL. After 12 weeks
of omalizumab treatment in this study, the mean AE-
QoL total score declined significantly from 56.2 to 27.7,
which changed the AE-QoL category of patients from
“moderate to large effect” to “small effect” of RAE on
HRQoL [13].
The strengths of this study include the use of three
different approaches to establish the MCID of the Thai
AE-QoL. However, several limitations should be noted
including its small study population and the very high
predominance of RAE patients with CSU. Secondly,
no patients with HAE were enrolled in this study.
Angioedema activity in HAE is generally more severe
than in other causes of angioedema. Kulthanan, et al.
reported that HAE was observed in 1 out of 105.
Lastly, the AE-QoL did not differentiate between
patients with moderate and large effect as measured
by PGA-QoL or DLQI in this study. Further studies
in larger study populations that include patients with
high disease activity and causes of RAE other than
CSU are needed to confirm the categorization of the
AE-QoL.”
Conclusion
The Thai version of AE-QoL was found to be a valid
and reliable instrument for assessing disease–specific
impact on QoL in Thai RAE patients. A change in AE-
QoL of > 6 points defines a meaningful change in
HRQoL. RAE patients should be categorized for the
impact of their disease on their QoL as those with “no
effect”, “small effect”, and “moderate to large effect”
based on AE-QoL total score values of up to 23, 24–38,
and 39 and higher, respectively.
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